Correction to: Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes
An amendment to this paper has been published and can be accessed via the original article.
Main Authors: | Christophe Pison, Pallav L. Shah, Dirk‑Jan Slebos, Vincent Ninane, Wim Janssens, Thierry Perez, Romain Kessler, Gaetan Deslee, Justin L. Garner, Jorine E. Hartman, Bruno Degano, Anna Mayr, Martin Mayse, Alexander D. Peterson, Arschang Valipour |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-03-01
|
Series: | Respiratory Research |
Online Access: | https://doi.org/10.1186/s12931-021-01678-z |
Similar Items
-
Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes
by: Pison Christophe, et al.
Published: (2021-02-01) -
Long-term safety of bilateral targeted lung denervation in patients with COPD
by: Valipour A, et al.
Published: (2018-07-01) -
Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira® lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3)
by: Dirk-Jan Slebos, et al.
Published: (2020-02-01) -
Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2
by: Valipour A, et al.
Published: (2020-11-01) -
Targeted lung denervation in sheep: durability of denervation and long-term histologic effects on bronchial wall and peribronchial structures
by: Martin L. Mayse, et al.
Published: (2020-05-01)